Huapont Life Sciences Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Huabang Life Health Co., Ltd. was established in 1992 and is a leading enterprise in the field of clinical skin medication and skin health in China. It was listed on the Shenzhen Stock Exchange in 2004 (stock code: 002004. SZ). After nearly 30 years of cultivation, the company has formed a development pattern with the big health industry as its main direction, and its business scope covers fields such as medicine, medical treatment, agrochemicals, new materials, tourism, etc. The company is currently a leading clinical dermatology drug service provider, pesticide leading enterprise, and industry leader in the fields of fine chemical intermediates and new materials in China. The company is headquartered in the Liangjiang New Area of Chongqing, a national level development zone. It has more than 100 participating holding companies in more than ten provinces and cities such as Chongqing, Sichuan, Beijing, Zhejiang, as well as overseas countries such as the United States, Germany, and Switzerland. With over 11000 employees worldwide, its products are sold to 58 countries and regions worldwide. The company currently controls one listed company, Lijiang Co., Ltd. (002033. SZ), and two companies listed on the New Third Board, Yingtai Biotechnology and Qinling Tourism. Yingtai Biotechnology is one of the first batch of companies listed on the selected layer of the New Third Board. In addition, the company spun off its controlling subsidiary, Kaisheng New Materials, to be listed on the Shenzhen Stock Exchange Growth Enterprise Board. The China Securities Regulatory Commission approved the registration application for Kaisheng New Materials' initial public offering of shares on August 11, 2021. As a national high-tech enterprise, the company adheres to the business philosophy of "Xinghua Xia Bang, Building a Healthy Great Wall", attaches great importance to product research and development and technological innovation. The field of drug treatment covers skin, tuberculosis, respiration, anti infection, tumor, ophthalmology, etc. The company currently has 2 first class new drugs, more than 20 first class products, 13 drugs (product specifications) that have been evaluated through consistency, and multiple products have been included in the national key new product plan. It has obtained more than 420 patent authorizations, Multiple production processes and technologies are in a leading position both domestically and internationally. In the future, the company will adhere to the core of the big health industry, gradually improve the entire industry chain development model that integrates raw materials, preparations, cosmetics, medical beauty, and medical services, and strive to build "Huabang" into the first brand of skin health in China. （1） The pharmaceutical business is engaged in the research and development, production, and sales of pharmaceutical preparations and raw materials, as well as the academic promotion of agent pharmaceutical products. In terms of preparations, the company relies on its subsidiary "Huabang Pharmaceutical" and multiple professional brands, starting from common personal skin diseases, to build the most profound and extensive product matrix, meeting the comprehensive and multi-level needs of skin health, treatment, and rehabilitation for customers of all ages. After nearly 30 years of cultivation, the product brand has been widely recognized and enjoys a high reputation in the industry. The company adopts a marketing model that combines academic promotion and off campus retail, and has established a sales team of over a thousand people, covering tens of thousands of hospitals, tens of thousands of grassroots medical institutions, tens of thousands of chain pharmacies and individual pharmacies in society. While consolidating the market share within the hospital, we actively implement product positioning upgrades, vigorously develop channels such as pharmacies, third-party terminals, and e-commerce, transform from the hospital to the hospital, and continuously increase the market share outside the hospital. In terms of raw material drugs, the company has two major raw material drug production enterprises: Huabang Shengkai and Hanjiang Pharmaceutical. Among them, Huabang Shengkai mainly produces skin, anti-tuberculosis, anti-tumor raw materials, etc. The products not only meet internal supply, but also achieve domestic and international sales. Hanjiang Pharmaceutical's products include steroid hormones, insect repellents, respiratory and digestive raw materials. They are export oriented and mainly sold to developed countries such as Europe, America, and Japan. They have established long-term cooperative relationships with internationally renowned pharmaceutical companies such as Abbott, Johnson&Johnson, Lilly, and MSD. （2） The medical business company began to expand its medical service field in 2015 through acquisitions, new establishment, and equity participation, introducing high-quality foreign medical service systems and treatment methods to China, providing specialized and personalized medical services for patients, and building a health industry brand in the fields of comprehensive medical care, rehabilitation treatment, medical aesthetics, and anti-tumor treatment. Currently operating traditional Chinese medicine hospitals include Chongqing North Kuanren Hospital, Beijing Huasheng Rehabilitation Hospital, Mann Skin Beauty Hospital (chain), Rheinland Rehabilitation Hospital in Germany, and Paracel Biotherapy Center in Switzerland. （3） The main business entity of the Agrochemical Business Company is Yingtai Biotechnology, mainly engaged in the research and development, production, and GLP technical services of pesticide raw materials, intermediates, and formulation products. It has the first GLP laboratory certified by OECD in Chinese Mainland, and has obtained more than 170 national patents. Yingtai Biotech ranked second in the sales of national pesticide enterprises in 2019 (excluding multinational companies acquired by China National Chemical Corporation) and tenth in the sales of global pesticide enterprises, with its comprehensive strength widely recognized at home and abroad.Yingtai Biotechnology has established extensive cooperative relationships with a large number of internationally renowned agricultural and chemical enterprises, such as ADAMA (Andoma), CORTEVA (Dow DuPont), NUFARM (Newham), and LANXESS (Langsheng). Based on the development strategy of returning to the "big health of medicine", Yingtai Biotechnology actively promotes the division of sectors and officially landed on the selected layer of the New Third Board on July 27, 2020, becoming one of the first batch of selected layer listed enterprises in China. （4） The New Materials Business Company's new materials business is mainly operated by Shandong Kaisheng New Materials, mainly engaged in the research and development, production, and sales of fine chemical products and new polymer materials. Its main products include sulfoxide chloride (thionyl chloride), high-purity aramid polymer monomers (meta/para phthaloyl chloride), para nitrobenzoyl chloride, chloroethers, polyether ketone ketones, etc. Kaisheng New Materials is the world's largest production base for sulfoxide chloride, a leading supplier of aramid polymer monomers in China, and also the third global enterprise to achieve the industrialization of polyether ketone ketone, with strong core technology and industrial competitiveness. At present, the company spins off Kaisheng New Materials and is listed on the Shenzhen Stock Exchange Growth Enterprise Board. The China Securities Regulatory Commission approved the registration application for Kaisheng New Materials' initial public offering of shares on August 11, 2021. （5） The tourism business company began to invest in tourism in 1999, with a diversified business model and a spread of operations from Chongqing to multiple regions across the country. Currently, it has rich tourism resources and mature experience in scenic area operation. The company's tourism resources are widely distributed in five major 5A scenic spots in Yunnan, Shaanxi, Chongqing, Guangxi and other provinces, municipalities directly under the Central Government, and autonomous regions, including Lijiang Yulong Snow Mountain Scenic Spot, the Old Town of Lijiang, Shaanxi Taibai Mountain National Forest Park, Chongqing Wulong Fairy Mountain National Forest Park, and Guangxi Detian Transnational Waterfall. The business scope covers scenic area development and operation, hotel management, cableway transportation, scenic area transportation, live performances, catering business, and travel agency services. |
| Headquarter | Chongqing |
| Establish Date | 3/11/1992 |
| Listed Code | 002004.SZ |
| Listed Date | 6/25/2004 |
| Chairman | Zhang Songshan. |
| CEO | Zhang Hai'an. |
| Website | www.huapont.com.cn |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
